You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | 0.0% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -2.7 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 0.0 | n/a |
Price / Book value | 1.7 |
Latest | Forecast | |
---|---|---|
Revenue | n/a | n/a |
PBT | 0.0% | n/a |
EPS | 0.0% | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2020-12-31 | n/a | -0.51 | -1.89p | 0.0 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | n/a | -2.53 | -6.02p | -4.9 | 0.0 | n/a | n/a | 0.0% |
Michael Kauffman promoted to BiVictriX board chair Sharecast News | 06 Jan |
---|---|
BiVictriX identifies development lead for potential cancer drug Sharecast News | 07 Dec |
BiVictriX upbeat on recent pipeline progress Sharecast News | 11 Jul |
Appointment of Alex Hughes as CFO | 01-Mar-23 15:46 |
---|---|
BiVictriX reports positive BVX001 preclinical data | 31-Jan-23 14:56 |
Holding(s) in Company | 24-Jan-23 23:59 |
Holding(s) in Company | 19-Jan-23 19:25 |
Holding(s) in Company | 19-Jan-23 14:23 |